Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice

Neurosci Lett. 1988 Oct 5;92(2):207-12. doi: 10.1016/0304-3940(88)90062-6.

Abstract

Injection of a low dose of haloperidol, that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and sensory neglect in MPTP-treated mice. GM1 ganglioside treatment eliminates all of these behavioral impairments and also partially restores striatal dopamine content. These observations suggest that the MPTP-treated mouse may be a valuable model for studying mechanisms underlying parkinsonism and that administration of GM1 ganglioside may be an effective therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Antipsychotic Agents / pharmacology
  • Behavior, Animal / drug effects
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Corpus Striatum / physiopathology
  • Dopamine / metabolism*
  • G(M1) Ganglioside / therapeutic use*
  • Haloperidol / pharmacology*
  • Male
  • Mice
  • Movement Disorders / chemically induced
  • Movement Disorders / drug therapy*
  • Movement Disorders / metabolism
  • Pyridines / administration & dosage*

Substances

  • Antipsychotic Agents
  • Pyridines
  • G(M1) Ganglioside
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Haloperidol
  • Dopamine